Biotage 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Frederic Vanderhaegen

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

CEO

Frederic Vanderhaegen (57 yo)

less than a year

테뉴어

Mr. Frederic Vanderhaegen is Chief Executive Officer & President of Biotage AB (publ) from September 16, 2024. Mr. Vanderhaegen joined the Biotage AB (publ) on September 16, 2024. Mr. Frederic was Executiv...

리더십 팀

이름	위치	테뉴어	보상	소유권
Frederic Vanderhaegen	Chief Executive Officer & President	less than a year	데이터 없음	데이터 없음
Andrew Kellett	Chief Financial Officer	1.2yrs	데이터 없음	데이터 없음
Anders Wikstrom	Executive Vice President of Operations	14.5yrs	데이터 없음	0.0064% € 67.3k
Raffaella Bombarda	EVP of Global Marketing	no data	데이터 없음	데이터 없음
Petra Duprez	Chief Human Resources & Sustainability Officer	no data	데이터 없음	0.019% € 198.5k
Scott Carr	President of Americas & Chief/Head of Americas	no data	데이터 없음	0.010% € 106.4k
Jonas Stahlberg	Chief Auditor	no data	데이터 없음	데이터 없음
Olof Nord	Executive Vice President of Business Development	no data	데이터 없음	0.025% € 263.9k
Andreas Juhlin	President of International - EMEA and APAC	4.4yrs	데이터 없음	0.0064% € 67.3k
Magnus Nordstedt	Executive Vice President of IT & Digitalization	no data	데이터 없음	0.0059% € 61.5k
Lisa Egelrud	Executive Vice President of Quality Assurance & Regulatory Affairs	3.8yrs	데이터 없음	데이터 없음
Maryam Poorafshar	Executive Vice President R&D	no data	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 관리: PQX1 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Torben Jorgensen	Director	5yrs	SEK 857.00k	0.40% € 4.2m
Kieran Murphy	Chairman	1.6yrs	SEK 227.00k	데이터 없음
Peter von Ehrenheim	Director	11.6yrs	SEK 407.00k	0.020% € 209.7k
Asa Hedin	Director	5yrs	SEK 337.00k	데이터 없음
Mark Bradley	Director	5.6yrs	SEK 307.00k	데이터 없음
Kugan Sathiyanandarajah	Director	1.6yrs	데이터 없음	데이터 없음
Dan Menasco	Employee Representative Director	2.9yrs	데이터 없음	데이터 없음
Karen Soerensen	Director	2.6yrs	SEK 357.00k	데이터 없음
Par Lundgren	Employee Representative Director	no data	데이터 없음	데이터 없음
Philip Lamberstam	Employee Representative Director	less than a year	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: PQX1 의 이사회는 경험(평균 재직 기간 2.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Biotage 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Biotage AB Appoints Nomination Committee

Biotage AB Announces Chief Executive Officer Changes, Effective September 16, 2024

Biotage Appoints Andrew Kellett as CFO

Biotage AB (publ) Announces CEO Changes

Biotage AB (publ), Annual General Meeting, Apr 25, 2024

Biotage AB (Publ) Announces Executive Changes

Recent updates

Third quarter 2024 earnings released: EPS: kr0.56 (vs kr0.47 in 3Q 2023)

Biotage AB (publ) to Report Fiscal Year 2024 Final Results on Apr 03, 2025

Biotage AB Appoints Nomination Committee

Biotage AB (publ) to Report First Half, 2025 Results on Jul 16, 2025

Biotage AB Announces Chief Executive Officer Changes, Effective September 16, 2024

KKR Reportedly Mulls Options for Stake in Biotage

KKR Reportedly Mulls Options for Stake in Biotage

Second quarter 2024 earnings released: EPS: kr0.60 (vs kr0.49 in 2Q 2023)

Biotage AB (Publ) Approves a Dividend, Payable on May 3, 2024

First quarter 2024 earnings released: EPS: kr0.42 (vs kr0.65 in 1Q 2023)

Upcoming dividend of kr1.60 per share

Full year 2023 earnings released: EPS: kr3.33 (vs kr4.06 in FY 2022)

Dividend of kr1.60 announced

Full year 2023 earnings released: EPS: kr3.33 (vs kr4.06 in FY 2022)

Investor sentiment improves as stock rises 17%

Biotage Appoints Andrew Kellett as CFO

Now 21% overvalued after recent price rise

Biotage AB (publ) Announces CEO Changes

Now 20% undervalued

Investor sentiment improves as stock rises 20%

Third quarter 2023 earnings released

New minor risk - Share price stability

Now 21% undervalued after recent price drop

Biotage AB (publ), Annual General Meeting, Apr 25, 2024

Biotage AB (Publ) Announces Executive Changes

Biotage AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Second quarter 2023 earnings released

Now 24% undervalued after recent price drop

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 24%

Director recently bought €178k worth of stock

Upcoming dividend of kr1.60 per share at 1.3% yield

Full year 2022 earnings released: EPS: kr4.06 (vs kr3.14 in FY 2021)

Biotage AB (Publ) Proposes Dividend for 2022

Full year 2022 earnings released: EPS: kr4.06 (vs kr3.14 in FY 2021)

No independent directors

Third quarter 2022 earnings released

Biotage AB (publ) Appoints Nomination Committee

Biotage AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Second quarter 2022 earnings released: EPS: kr0.86 (vs kr0.71 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released

No independent directors

Upcoming dividend of kr1.55 per share

Full year 2021 earnings released: EPS: kr3.14 (vs kr2.68 in FY 2020)

Investor sentiment improved over the past week

Biotage AB (Publ) Proposes Dividend for 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS kr0.70 (vs kr0.49 in 2Q 2020)

Biotage Announces the Launch of Biotage® Phyprep

Executive Vice president of Operations recently sold €26k worth of stock

Executive Vice president of Operations recently sold €26k worth of stock

First quarter 2021 earnings released: EPS kr0.92 (vs kr0.94 in 1Q 2020)

Biotage AB Approves Dividend, Payable on 5 May 2021

Upcoming dividend of kr1.50 per share

Full year 2020 earnings released: EPS kr2.69 (vs kr2.87 in FY 2019)

Revenue beats expectations

New 90-day high: €16.72

Full year 2020 earnings released: EPS kr2.69 (vs kr2.87 in FY 2019)

New 90-day low: €12.71

New 90-day low: €13.32

Revenue misses expectations

Third quarter 2020 earnings released: EPS kr0.57

Biotage AB to Report First Half, 2021 Results on Jul 16, 2021

New 90-day low: €14.12

Director recently sold €249k worth of stock

Biotage AB Announces Executive Changes